PR Newswire
Tyra Biosciences to Participate in Upcoming Investor Conferences
📊
AI Sentiment
Positive
6/10
- Home
- TYRA
as of 02-26-2026 9:39am EST
$34.28
$0.38
-1.10%
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 1.2B | IPO Year: | 2021 |
| Target Price: | $44.63 | AVG Volume (30 days): | 729.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | 6.79 |
| 52 Week Low/High: | $6.42 - $35.71 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -23.90 | Index: | N/A |
| Free Cash Flow: | -70438000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)
Bensen Daniel
Sell
Chief Discovery Officer
TYRA Feb 12, 2026
Avg Cost/Share
$32.43
Shares
8,000
Total Value
$262,964.51
Owned After
152,853
Bensen Daniel
Sell
Chief Discovery Officer
TYRA Jan 12, 2026
Avg Cost/Share
$28.76
Shares
8,000
Total Value
$228,185.66
Owned After
152,853
Bensen Daniel
Sell
Chief Discovery Officer
TYRA Dec 12, 2025
Avg Cost/Share
$22.64
Shares
8,000
Total Value
$181,159.20
Owned After
152,853
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bensen Daniel | TYRA | Chief Discovery Officer | Feb 12, 2026 | Sell | $32.43 | 8,000 | $262,964.51 | 152,853 | |
| Bensen Daniel | TYRA | Chief Discovery Officer | Jan 12, 2026 | Sell | $28.76 | 8,000 | $228,185.66 | 152,853 | |
| Bensen Daniel | TYRA | Chief Discovery Officer | Dec 12, 2025 | Sell | $22.64 | 8,000 | $181,159.20 | 152,853 |
Latest Tyra Biosciences Inc. News
TYRA Breaking Stock News: Dive into TYRA Ticker-Specific Updates for Smart Investing
Compare TYRA vs Leading Stocks
See how TYRA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TYRA Tyra Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.